← All comparisons
Head-to-head · FAERS comparison

Omeprazole vs Ranitidine: side effects in FDA adverse event reports

How to read this page. FAERS report counts have no denominator; the comparison is of reporting patterns, not of risk. Signals are screened against each FDA label (badges) but not causally assessed. Not medical advice.

At a glance

OmeprazoleRanitidine
Drug classProton Pump Inhibitor–
Brand names––
FAERS reports444,238197,701
Serious72%93%
Death outcome39,12115,520
Boxed warningNoNo

Signals both drugs share

ReactionOmeprazoleRanitidineLabel screen (A / B)
Chronic kidney disease-mineral and bone disorder753 · PRR 111.0149 · PRR 16.9Not in label — unassessed / Not in label — unassessed

Labeled signals distinctive to Omeprazole

Labeled signals distinctive to Ranitidine

  • None stood out among the strongest labeled signals.

Common questions

Which has more reported side effects, Omeprazole or Ranitidine?

Omeprazole has 444,238 FAERS reports and Ranitidine 197,701. More reports does not mean more dangerous: volume follows how widely and how long a drug has been used, prescription vs over-the-counter status, and publicity. The seriousness share (72% vs 93%) is a better like-for-like signal of the kind of problems reported.

Which side effects do Omeprazole and Ranitidine share?

Both drugs carry disproportionality signals for chronic kidney disease-mineral and bone disorder. Shared signals often reflect a shared drug class or the condition both are used for.

Is Omeprazole or Ranitidine safer?

FAERS cannot answer that: it has no denominator and no comparator. Use this page to see which risks are already on each label and which signals are unlabeled, then check the prescribing information and your clinician for your situation.

Sources: openFDA FAERS pair statistics (OpenPV build 2026-09-14), FDA labels via openFDA, openFDA count queries for seriousness and deaths. Pair chosen because it is a commonly searched comparison. Generated 2026-10-08.